Deeplife
Designs and builds incredibly complex mechanical engines, engineering biological systems, such as cells, remains a challenge.
- dt and ls
- biotechnology
- core ai
- radar de l'innovation
- ai applications
- tech for business
- genetics and genomics
- observatoire deeptech
- drug development
- genome engineering
- biotech, medtech and e-health
- nif defense security and resilience
- ai drug discovery
- techbio
- digital pharma
- techbio drug discovery
- nif health crisis preparedness
- digital twin
- nif biotech
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor | €0.0 | round |
| investor | €0.0 | round | |
| investor investor investor investor investor investor investor investor | €0.0 | round | |
* | $10.0m | Series A | |
| Total Funding | 000k | ||
Related Content
Founded in 2019 by Jonathan Baptista and Jean-Baptiste Morlot, DeepLife is a startup developing a SaaS platform for creating digital twins of cells. The company aims to address the challenge of engineering biological systems by leveraging advancements in biochemistry and the availability of large-scale quantitative cell activity data.
The platform developed by the DeepLife team utilizes deep learning algorithms on multi-omics sequencing data, along with public and private cell atlases and proprietary cell engineering tools. The primary goal is to supplement traditional in vitro testing with in silico simulations, enabling the rapid discovery of molecular triggers to engineer cell behavior efficiently.
DeepLife collaborates with biotech and pharmaceutical companies to expedite their target identification processes. The company also maintains a strong connection with the academic community through the publication of research papers and by providing open access to its platform's features and data.
Keywords: digital twin of cells, SaaS platform, deep learning, multi-omics sequencing, cell engineering, target identification, in silico simulations, biotech, pharmaceutical, academic collaboration